(ps4) Selventa Development of A Therapeutic Diagnostic? Stratification Biomarker for Drug Response in Ulcerative Colitis

摘要

Using a gene expression data set from Ulcerative Colitis patients treated with Infliximab with objective response criteria as input data and our proprietary Selventa analytics, we have developed a disease classifier which identifies alternative molecular mechanisms driving the disease beyond TNF-alpha, the target of Infliximab. This Therapeutic DiagnosticTM classifier identifies at least 3 more strong, independent disease drivers, including IL-6, and provides the opportunity to stratify patient a priori by molecular disease mechanism and associated treatment(s). In the case of IL6 we provide supporting evidence in a related disease that indicates the complementary nature of the TNFalpha and IL-6 disease driving mechanisms, as a partial validation of the approach. This approach does not rely on response data to develop classifiers and is easily generalized to deliver patient stratification for any specific disease population in Early Discovery with an optimized project portfolio as a result.